Specific chemical substances, compositions, and methods

Crystalline N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide effectively inhibits Raf kinase activity, addressing abnormal cell proliferation in cancer by providing stable and selective inhibition.

JP7891985B2Inactive Publication Date: 2026-07-23NEUPHARMA INC
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
NEUPHARMA INC
Filing Date
2021-12-01
Publication Date
2026-07-23
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing kinase inhibitors do not effectively address abnormal cell proliferation and differentiation, particularly in cancer-related processes, due to lack of specific modulation of tyrosine and serine/threonine kinase activity.

Method used

Development of crystalline forms of N-(2,4,5-trifluoro-3-(3-morpholinoquinoxaline-6-carbonyl)phenyl)propane-1-sulfonamide, characterized by specific X-ray powder diffraction patterns and thermal properties, which act as potent and selective Raf kinase inhibitors.

Benefits of technology

The crystalline forms provide stable and effective inhibition of Raf kinase activity, offering therapeutic benefits for various cancers by regulating cell proliferation and differentiation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007891985000010
    Figure 0007891985000010
  • Figure 0007891985000011
    Figure 0007891985000011
  • Figure 0007891985000012
    Figure 0007891985000012
Patent Text Reader

Abstract

Novel chemical compounds, their polymorphs, pharmaceutical compositions, and methods for treating cancer are described.
Need to check novelty before this filing date? Find Prior Art